669 related articles for article (PubMed ID: 17383140)
61. In vitro activity of fluoroquinolones, vancomycin, and gentamicin against methicillin-resistant Staphylococcus aureus ocular isolates.
Kotlus BS; Wymbs RA; Vellozzi EM; Udell IJ
Am J Ophthalmol; 2006 Nov; 142(5):726-9. PubMed ID: 17056356
[TBL] [Abstract][Full Text] [Related]
62. Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12).
Sader HS; Farrell DJ; Castanheira M; Flamm RK; Jones RN
J Antimicrob Chemother; 2014 Oct; 69(10):2713-22. PubMed ID: 24917579
[TBL] [Abstract][Full Text] [Related]
63. Antimicrobial activities of doripenem and other carbapenems against Pseudomonas aeruginosa, other nonfermentative bacilli, and Aeromonas spp.
Castanheira M; Jones RN; Livermore DM
Diagn Microbiol Infect Dis; 2009 Apr; 63(4):426-33. PubMed ID: 19249180
[TBL] [Abstract][Full Text] [Related]
64. Nationwide surveillance in Taiwan of the in-vitro activity of tigecycline against clinical isolates of extended-spectrum beta-lactamase-producing Enterobacteriaceae.
Lu CT; Chuang YC; Sun W; Liu YC; Cheng YJ; Lu PL; Chen CM; Hsu GJ; Jang TN; Lee CM; Chiang PC; Shi ZY; Wang LS; Kung HC; Lin HC; Liao CH; Liu JW; Huang CH; Tsao SM; Hsueh PR
Int J Antimicrob Agents; 2008 Nov; 32 Suppl 3():S179-83. PubMed ID: 19013351
[TBL] [Abstract][Full Text] [Related]
65. Epidemiology and antimicrobial susceptibility profiles of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region: 2008 results from SMART (Study for Monitoring Antimicrobial Resistance Trends).
Hsueh PR; Badal RE; Hawser SP; Hoban DJ; Bouchillon SK; Ni Y; Paterson DL;
Int J Antimicrob Agents; 2010 Nov; 36(5):408-14. PubMed ID: 20728316
[TBL] [Abstract][Full Text] [Related]
66. Emergence of high-level fluoroquinolone resistance in emm6 Streptococcus pyogenes and in vitro resistance selection with ciprofloxacin, levofloxacin and moxifloxacin.
Malhotra-Kumar S; Van Heirstraeten L; Lammens C; Chapelle S; Goossens H
J Antimicrob Chemother; 2009 May; 63(5):886-94. PubMed ID: 19279051
[TBL] [Abstract][Full Text] [Related]
67. Comparative antimicrobial spectrum and activity of BMS284756 (T-3811; a desfluoroquinolone) tested against an international collection of staphylococci and enterococci, including in vitro test development and intermethod comparisons.
Pfaller MA; Beach ML; Gordon KA; Jones RN
J Chemother; 2002 Feb; 14(1):13-8. PubMed ID: 11892893
[TBL] [Abstract][Full Text] [Related]
68. [Comparative in vitro activity of 10 new 4-quinolones against enteropathogenic bacteria].
Habiyaremye I; Verbist L; Vandepitte J
Pathol Biol (Paris); 1987 Jun; 35(5 Pt 2):800-4. PubMed ID: 3116489
[TBL] [Abstract][Full Text] [Related]
69. Reevaluation of the cefepime minimal inhibitory concentrations and disk diffusion test zone diameter relationship for a worldwide collection of Enterobacteriaceae enriched for extended-spectrum beta-lactamase-producing organisms.
Pottumarthy S; Deshpande LM; Sader HS; Jones RN
Diagn Microbiol Infect Dis; 2005 Jun; 52(2):95-9. PubMed ID: 15964496
[TBL] [Abstract][Full Text] [Related]
70. Resistance of uropathogens in symptomatic urinary tract infections in León, Nicaragua.
Matute AJ; Hak E; Schurink CA; McArthur A; Alonso E; Paniagua M; Van Asbeck E; Roskott AM; Froeling F; Rozenberg-Arska M; Hoepelman IM
Int J Antimicrob Agents; 2004 May; 23(5):506-9. PubMed ID: 15120732
[TBL] [Abstract][Full Text] [Related]
71. Comparative activity of meropenem in US medical centers (2007): initiating the 2nd decade of MYSTIC program surveillance.
Jones RN; Kirby JT; Rhomberg PR
Diagn Microbiol Infect Dis; 2008 Jun; 61(2):203-13. PubMed ID: 18329835
[TBL] [Abstract][Full Text] [Related]
72. In vitro activity of sitafloxacin compared with several fluoroquinolones against Streptococcus anginosus and Streptococcus constellatus.
Yamamoto N; Fujita J; Shinzato T; Higa F; Tateyama M; Tohyama M; Nakasone I; Yamane N
Int J Antimicrob Agents; 2006 Feb; 27(2):171-3. PubMed ID: 16417990
[TBL] [Abstract][Full Text] [Related]
73. Cefdinir activity against contemporary North American isolates from community-acquired urinary tract infections.
Sader HS; Biedenbach DJ; Streit JM; Jones RN
Int J Antimicrob Agents; 2005 Jan; 25(1):89-92. PubMed ID: 15620832
[TBL] [Abstract][Full Text] [Related]
74. MYSTIC Europe 2007: activity of meropenem and other broad-spectrum agents against nosocomial isolates.
Turner PJ
Diagn Microbiol Infect Dis; 2009 Feb; 63(2):217-22. PubMed ID: 19070453
[TBL] [Abstract][Full Text] [Related]
75. Antibiotic resistance in outpatient urinary isolates: final results from the North American Urinary Tract Infection Collaborative Alliance (NAUTICA).
Zhanel GG; Hisanaga TL; Laing NM; DeCorby MR; Nichol KA; Palatnik LP; Johnson J; Noreddin A; Harding GK; Nicolle LE; Hoban DJ;
Int J Antimicrob Agents; 2005 Nov; 26(5):380-8. PubMed ID: 16243229
[TBL] [Abstract][Full Text] [Related]
76. Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin-resistant enterococci isolated in European medical centers (2005).
Sader HS; Watters AA; Fritsche TR; Jones RN
BMC Infect Dis; 2007 Apr; 7():29. PubMed ID: 17442104
[TBL] [Abstract][Full Text] [Related]
77. Comparative In Vitro Activities of Moxifloxacin (Bay 12-8039) and Other Antimicrobial Agents Against Respiratory Tract Pathogens in Brazil.
Del' Alamo L ; Sampaio J; Miranda EA; Sader HS
Braz J Infect Dis; 1999 Dec; 3(6):215-219. PubMed ID: 11084671
[TBL] [Abstract][Full Text] [Related]
78. In vitro activity of cefditoren and other antimicrobial agents against 288 Streptococcus pneumoniae and 220 Haemophilus influenzae clinical strains isolated in Zaragoza, Spain.
Seral C; Suárez L; Rubio-Calvo C; Gómez-Lus R; Gimeno M; Coronel P; Durán E; Becerril R; Oca M; Castillo FJ
Diagn Microbiol Infect Dis; 2008 Oct; 62(2):210-5. PubMed ID: 18715733
[TBL] [Abstract][Full Text] [Related]
79. Susceptibility of Mexican brucella isolates to moxifloxacin, ciprofloxacin and other antimicrobials used in the treatment of human brucellosis.
López-Merino A; Contreras-Rodríguez A; Migranas-Ortiz R; Orrantia-Gradín R; Hernández-Oliva GM; Gutiérrez-Rubio AT; Cardeñosa O
Scand J Infect Dis; 2004; 36(9):636-8. PubMed ID: 15370648
[TBL] [Abstract][Full Text] [Related]
80. Tigecycline activity tested against 11808 bacterial pathogens recently collected from US medical centers.
Gales AC; Sader HS; Fritsche TR
Diagn Microbiol Infect Dis; 2008 Apr; 60(4):421-7. PubMed ID: 18068934
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
